secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052110
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q1 net loss $81.4M; cash $749.6M, Genentech milestone boosts revenue
--------------------------------------------------------------------------------

- Net loss $81.4M ($0.62/share) vs $94.2M ($0.78/share) in Q1 2023; loss narrowed.
- Revenue $10.0M vs $0.2M YoY, driven by $10M milestone from Genentech collaboration.
- Cash and investments $749.6M, expected to fund operations into H2 2026.
- R&D expenses $82.4M, relatively flat vs $82.8M year ago.
- RLY-2608 doublet and triplet trials enrolling; lirafugratinib data and regulatory update expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/0000950170-24-052110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/rlay-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer